Albumedix Appoints Chief Medical Officer

Dr. Giles Campion has been appointed chief medical officer, Albumedix A/S. Dr. Campion has more than 25 years of experience in drug development from both large pharma and biopharma companies having held senior development positions in the U.S. and Europe.
 
Dr. Campion will be responsible for leading the company’s global development efforts, establishing a proprietary pipeline, as well as strengthening the company’s partnered drug pipeline. He will join Albumedix’s executive management team, reporting to chief executive officer, Peter Rosholm.
 
Dr. Campion previously served as senior vice president of R&D and CMO at Prosensa Holdings and then group vice president, Neuromuscular Franchise at Biomarin following the Prosensa acquisition. He also held positions such as Global Head of Clinical Research and Development at GE Healthcare and European Head of Exploratory Clinical Development at Novartis. During his career, he has been responsible for the development of more than 40 therapeutics and diagnostic agents.
 
Peter Rosholm said, "I am delighted to welcome Giles Campion to Albumedix. His depth of experience across a broad range of therapeutic indications, drug development track record and expertise in the filings of specialized pharmaceuticals, will be invaluable to us as we move our pre-clinical drug candidates towards the clinic. The appointment marks the latest step in our growth strategy as we work to advance breakthroughs in the use of albumin based technologies in the development of life-changing therapeutics."